Eloxx Pharmaceuticals, Inc.
ELOXD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ELOXD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ELOXD
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing exaluren, a novel therapeutic candidate for nonsense mutation disorders, currently facing significant financial constraints and a going concern risk.
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$40.9M
Cash Runway
—
Lead Asset
zkn-013 (Preclinical)
Next Catalyst
—
Tracking 1 pipeline candidate for Eloxx Pharmaceuticals, Inc..
Similar companies
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing exaluren, a novel therapeutic candidate for nonsense mutation disorders, currently facing significant financial constraints and a going concern risk.
- Lead product candidate is exaluren, a potential treatment for genetic disorders caused by nonsense mutations [sec_mda · as of 2026-08-11].
- Company has no approved products and has incurred net losses; latest quarterly net income was -$4.5M as of 2026-06-30 [sec].
- Cash and equivalents totaled $62.0M as of 2026-06-30, but the company states it does not have adequate funds to conduct planned clinical trials [sec · filed 2026-05-07].
- Shareholders' equity was -$27.9M as of 2026-06-30, indicating an accumulated deficit and financial strain [sec].
- Company faces risks related to its ability to continue as a going concern and to uplist its shares to the Nasdaq Capital Market [sec · filed 2026-05-07].
What works
- Exaluren targets a well-defined genetic mechanism (nonsense mutations) with potential applicability across multiple rare diseases [sec_mda · as of 2026-08-11].
- The company has ongoing preclinical and clinical development activities for exaluren, indicating progress in its pipeline [sec_mda · as of 2026-08-11].
- No debt is reported as of 2026-06-30, providing some balance sheet flexibility [sec].
What to weigh
- The company has no approved products and has never generated revenue from product sales, relying entirely on external funding [sec_mda · as of 2026-08-11].
- Eloxx states it does not have adequate funds to conduct any of its planned clinical trials, creating substantial uncertainty about pipeline execution [sec · filed 2026-05-07].
- Negative shareholders' equity of -$27.9M as of 2026-06-30 reflects deep accumulated losses and financial distress [sec].
- The company faces a going concern risk and must secure additional capital to continue operations, which may be challenging [sec · filed 2026-05-07].
From the filings
Quoted directly from source documents.
Company does not have adequate funds to conduct planned clinical trials.
“We do not have adequate funds to conduct any of our planned clinical trials.”
SEC filings · May 7, 2026
Company's ability to continue as a going concern is uncertain.
“our ability to obtain the capital necessary to fund our operations and continue as a going concern;”
SEC filings · May 7, 2026
Lead product candidate is exaluren.
“our dependence on our lead product candidate, exaluren, and our ability to progress it through clinical trials;”
SEC filings · May 7, 2026
Company expects expenses to increase as it advances exaluren.
“We anticipate that our expenses may increase if, and as, we: • advance exaluren and/or other product candidates further into clinical development;”
SEC MD&A · August 11, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Company may not have sufficient capital to continue operations without additional funding [sec · filed 2026-05-07].
- Clinical trial funding gap — Company states it lacks adequate funds to conduct any planned clinical trials [sec · filed 2026-05-07].
- No approved products — No revenue from product sales; relies entirely on external financing [sec_mda · as of 2026-08-11].
- Nasdaq listing risk — Ability to uplist shares to Nasdaq Capital Market is uncertain [sec · filed 2026-05-07].
What to watch
- Ability to raise additional capital to fund operations and clinical trials [sec · filed 2026-05-07].
- Progress of exaluren through preclinical and clinical development [sec_mda · as of 2026-08-11].
- Outcome of efforts to uplist shares to the Nasdaq Capital Market [sec · filed 2026-05-07].
- Any updates on regulatory interactions or milestone payments under license agreements [sec · filed 2026-05-07].
Sources: SEC filings · SEC MD&A · Generated August 12, 2026 · How we verify sources →
Run Eloxx Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Eloxx Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Eloxx Pharmaceuticals, Inc.?
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing exaluren, a novel therapeutic candidate for nonsense mutation disorders, currently facing significant financial constraints and a going concern risk.
What is Eloxx Pharmaceuticals, Inc.'s lead drug candidate?
Eloxx Pharmaceuticals, Inc.'s most advanced tracked candidate is zkn-013 (Preclinical) for Familial Adenomatous Polyposis (FAP).
Who is the CEO of Eloxx Pharmaceuticals, Inc.?
Mr. Sumit Aggarwal M.B.A. is the chief executive officer of Eloxx Pharmaceuticals, Inc. (ELOXD).
Where is Eloxx Pharmaceuticals, Inc. headquartered?
Eloxx Pharmaceuticals, Inc. (ELOXD) is headquartered in Arlington, MA, United States.
What therapeutic areas does Eloxx Pharmaceuticals, Inc. focus on?
Eloxx Pharmaceuticals, Inc. develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.